The Glucotoxicity Protecting Effect of Ezetimibe in Pancreatic Beta Cells via Inhibition of CD36

Ji Sung Yoon,*, Jun Sung Moon,** Yong-Woon Kim,† Kyu Chang Won,† and Hyoung Woo Lee†

1Department of Internal Medicine, Yeungnam University College of Medicine, Daegu, Korea; 2Department of Physiology, Yeungnam University College of Medicine, Daegu, Korea

*Ji Sung Yoon and Jun Sung Moon contributed equally to this work.

Received: 23 April 2015 Accepted: 23 December 2015

Address for Correspondence: Hyoung Woo Lee, MD Department of Internal Medicine, Yeungnam University Hospital, 170 Hyeonchung-ro, Nam-gu, Daegu 42415, Korea E-mail: helee@med.yu.ac.kr

INTRODUCTION

Physiological level of glucose stimulates insulin secretion; however, chronic hyperglycemia causes insulin secretory dysfunction, known as glucotoxicity (1).

Fatty acids (FAs) are also important for insulin secretion; however, prolonged exposure to elevated levels of FAs causes pancreatic β-cell dysfunction and apoptosis, resulting in lipotoxicity, which is augmented by high glucose (2,3).

Cellular uptake of fatty acids involves two components of passive diffusion through the lipid bilayer and protein-facilitated transfer playing a major role in metabolic tissues. Several proteins, including fatty acid translocase/cluster determinant 36 (CD36), family of fatty acid transport proteins (FATPs) (1-6), and plasma-membrane-associated FA-binding protein (FABPpm) have been identified as active FAs transport proteins.

CD36 has been documented having an important role of FA transport, and it is mainly distributed in liver and muscle tissues. Recently it was reported that CD36 is also expressed in insulin producing cells including MIN-6 cell, INS-cell, and human β-cell (4).

A previous report demonstrated that high glucose stimulated CD36 expression and palmitate uptake in INS-1 cells along with decreased insulin secretion, which was normalized by suppression of CD36 (5).

Inhibition of CD36, a fatty acid transporter, has been reported to prevent glucotoxicity and ameliorate high glucose induced beta cell dysfunction. Ezetimibe is a selective cholesterol absorption inhibitor that blocks Niemann Pick C1-like 1 protein, but may exert its effect through suppression of CD36. We attempted to clarify the beneficial effect of ezetimibe on insulin secreting cells and to determine whether this effect is related to change of CD36 expression. mRNA expression of insulin and CD36, intracellular peroxide level and glucose stimulated insulin secretion (GSIS) under normal (5.6 mM) or high glucose (30 mM) condition in INS-1 cells and primary rat islet cells were compared. Changes of the aforementioned factors with treatment with ezetimibe (20 μM) under normal or high glucose condition were also assessed. mRNA expression of insulin was decreased with high glucose, which was reversed by ezetimibe in both INS-1 cells and primary rat islets. CD36 mRNA expression was increased with high glucose, but decreased by ezetimibe in INS-1 cells and primary rat islets. Three-day treatment with high glucose resulted in an increase in intracellular peroxide level; however, it was decreased by treatment with ezetimibe. Decrease in GSIS by three-day treatment with high glucose was reversed by ezetimibe. Palmitate uptake following exposure to high glucose conditions for three days was significantly elevated, which was reversed by ezetimibe in INS-1 cells. Ezetimibe may prevent glucotoxicity in pancreatic β-cells through a decrease in fatty acid influx via inhibition of CD36.

Keywords: Diabetes Mellitus; Beta Cells; Glucotoxicity; CD36; Ezetimibe
expression of CD13, CD16, CD64, and CD36 of monocyte-derived macrophages (9). Ezetimibe is also known to improve glucose metabolism in addition to lowering lipid levels in type 2 diabetes (10,11). Ezetimibe could inhibit the activity of hepatic NPC1L1, promoting the insulin signaling pathway, and then improve insulin resistance in the liver (12). Several studies with diabetic animal models have revealed that ezetimibe could improve first phase insulin secretion and protect β-cells (13,14), however, the specific mechanism is still unclear.

This study attempted to clarify the effects of ezetimibe on pancreatic secreting beta-cells exposed to high glucose and to determine whether these effects are related to change of CD36 expression.

MATERIALS AND METHODS

INS-1 cell culture
INS-1 cells were grown in 5% CO2 with 95% air at 37°C in RPMI-1640 medium (GIBCO, Grand Island, NY, USA) containing 11.1 mM pyruvate, 10 mM HEPES, 50 M 2-mercaptoethanol, 100 U penicillin/mL, and 100 g streptomycin/mL. The RPMI-1640 medium used in all experiments contained the supplements described above. The cells were passaged weekly after they had been detached with trypsin-EDTA. All experiments were performed using INS-1 cells between passages 21 and 29.

Pancreatic islet isolation and cell culture
Pancreases from male Sprague-Dawley rats weighing 180-250 grams were infused with 10 mL of 1.5 mg/mL collagenase type XI (Sigma, St. Louis, MO, USA)/1% fetal bovine serum/2 units/mL RQ1 DNase (Promega, Madison, WI, USA) solution in Medium 199 (Sigma). After surgical excision of the pancreas, it was incubated in collagenase solution at 37°C. Undigested tissue was removed using a 500 μm screen, and the recovered tissue was washed twice with ice-cold Hanks’ balanced salt solution containing 0.1% bovine serum albumin, followed by centrifugation at 250 x g for 4 minutes. Prior to experimentation, islets in the pellet were separated using a Histopaque-1077 gradient (Sigma), and islets were then hand-picked and cultured in RPMI medium 1640 containing 10% fetal bovine serum, 11.1 mM glucose, and penicillin/streptomycin/amphotericin B.

mRNA expression of insulin and CD36 and intracellular peroxide levels were determined in INS-1 cells and primary rat islet cells exposed under normal (5.6 mM for INS-1 cells, 11 mM for primary cells) or high glucose condition (30 mM for both) with or without 20 μM of ezetimibe for 12 hours. The dose of ezetimibe was determined according to previous studies with monocyte or CaCO2 cells (7,9). Glucotoxicity was induced by three-day treatment with high glucose (30 mM) and glucose stimulated insulin secretion (GSIS) in INS-1 cells was evaluated. INS-1 cells were exposed to high dose palmitate (1 mM) for 24 hours.

Evaluation of reactive oxygen species (ROS) with flow cytometry
Intracellular peroxide levels were detected by flow cytometric analysis using an oxidation-sensitive fluorescein labeled dye, carboxy-dichlorodi-hydrofluorescein diacetate (carboxy-H2DCFDA, Molecular Probes, Carlsbad, CA, USA) (15). Upon oxidation by intracellular ROS, the non-fluorescent dye is converted into its fluorescent form. INS-1 cells were labeled with 10 M carboxy-H2DCFDA for 1 hour at 37°C. Following cell loading of the dye, the cells were washed twice with PBS and then put back into culture conditions for 2 hours. INS-1 cells were then harvested, washed twice with PBS, and re-suspended in trypsin-EDTA (0.25% trypsin, 2 mM Na4-EDTA, Invitrogen) for 5 minutes at 37°C. In order to disperse the cells into a single cell suspension, INS-1 cells were gently passed 20 times in and out of a 200-1,000 lL tip. The cells were then washed twice with ice-cold PBS. Analysis of cells was performed using a 488 nm argon laser EPICS XL-MCL flow cytometer controlled by EXPO 32-ADC software (Beckman Coulter, Fullerton, CA, USA). ROS values were analyzed based on fluorescence intensity.

GSIS
Static incubation of the INS-1 rat isletoma cell line in Krebs-Ringer buffer (KRB) (118 mmol/L NaCl, 4.7 mmol/L KCl, 2.5 mmol/L CaCl2, 1.18 mmol/L KH2PO4, 1.18 mmol/L MgSO4, 25 mmol/L NaHCO3, 10 mmol/L HEPES, and 0.1% BSA, pH 7.4) containing either non-stimulatory or stimulatory concentrations of glucose (5.6 mM or 16.7 mM, respectively) was performed for 1 hour. Insulin levels in KRB media were collected from the static incubations from INS-1 cells using 95.5 ethanol: hydrochloric acid solution was measured using an enzyme-linked immunosorbent assay (Rat Insulin ELISA kit; Mercodia, Uppsala, Sweden).

Real time RT-PCR
Total RNA was obtained from INS-1 cells using Trizol Reagent (Bio Science Technology, Korea). cDNA was synthesized using 1 μg total RNA with oligo-(dT) primers and Prime RT Premix (GENET BIO, Korea). Real-time RT-PCR was performed in the Light-Cycler (Roche, Germany) as previously described. The following primers were used: insulin, 50-ACC CAA GTC CCG TCG CAA CAA-30 (forward) and 50-TCC AGG ACA TAT TCA CCA CAY-30 (reverse); PDX-1, 50-GGC TTA ACC TAA ACG TGA AGT-30 (forward) and 50-CCA GTT GGT AGA GGG AGC-30 (reverse); β-actin, 50-TCG ACC TGC TCC TAG CA-30 (forward) and 50-TGG ACA GTG AGG CCA GGA TAG-30 (reverse).

Palmitate uptake
Palmitate uptake was determined using a modified method re-
ported by Wallin et al. (4). Briefly, cells were trypsinized and washed in ice-cold KRB in the absence of glucose. An equal amount of cells was transferred to new tubes and centrifuged. Cells were re-suspended in ice-cold KRB (11.1 mmol/L glucose) and 2.1 lCi 14C-palmitate (Perkin Elemer Life Science Inc., Boston, MA, USA) and transferred to microcentrifuge tubes (50 IL), which were prepared with a bottom layer of 6 mol/L urea solution (20 IL) over layered by a 10:3 mixture of dibutyl-dinonylphthalate (200 IL). Uptake was terminated by centrifugation at 8,000 rpm for 15 minutes. The urea layer containing the cells was transferred into scintillation vials and radioactivity was measured after addition of scintillation cocktail (Aqueous Counting Scintillation, Amersham, Canada) using a liquid scintillation counter (Packard Bioscience Company, Meriden, CT, USA).

**Data analysis**

All values are expressed as mean ± SE. One-way ANOVA was used for statistical analysis, and the differences between groups were considered significant at \( P \) values < 0.05.

**RESULTS**

The mRNA expression of insulin was decreased in the high dose palmitate (1 mM) group, compared with the control group, whereas mRNA expression of CD36 and intracellular peroxide level were increased in INS-1 cells. However, no significant change was observed in glucose stimulated insulin secretion (GSIS) by palmitate (data not shown).

The effects of high glucose (30 mM) with or without ezetimibe for 12 hours on insulin secreting cells are shown in Fig. 1. The high glucose group showed increased CD36 mRNA expression and decreased insulin mRNA expression. Ezetimibe per se in normal glucose media induced no changes in mRNA expression of CD36 and insulin. However, treatment with ezetimibe in high glucose showed that the increased CD36 mRNA expression in high glucose was suppressed and decreased insulin mRNA expression was reversed with ezetimibe (Fig. 1A and B). Similar results were observed again in primary rat islet cells (Fig. 1C and D).

Three-day exposure of INS-1 cells to 30 mM glucose for induction of glucotoxicity resulted in an increase in palmitate uptake which was decreased by treatment with ezetimibe (Fig. 2A). An increase in Intracellular peroxide level and a decrease in GSIS were induced with three-day exposure of high glucose; however, ezetimibe induced a significant decrease in intracellular peroxide level and reversal of GSIS (Fig. 2B and C).

![Fig. 1](http://dx.doi.org/10.3346/jkms.2016.31.4.547)
demonstrated that high levels of FAs led to an increase in oxidative stress, resulting in glucolipotoxicity (1). Findings of the present study suggested that prolonged exposure to elevated FAs along with high glucose causes pancreatic b-cell dysfunction and apoptosis, resulting in glucolipotoxicity (1). Findings of the present study demonstrated that high levels of FAs led to an increase in oxidative stress and a decrease in insulin mRNA expression, but did not cause impairment of GSIS. The reasons why the effects of FAs on beta cell dysfunction in vitro have been various are the differences of sensitivity to the cytotoxic effects of FAs between clonal cells and primary beta cells, and the disparity of concentration of FAs used in vitro, and lack of concern for the concentration of potent FAs fraction unbound to bovine serum albumin (BSA) (1).

The finding that high glucose condition in normal FA concentration increased intracellular uptake of FAs was shown again in the present study along with our previous study (5). This finding implies that the conditions inducing high FA influx may result in insulin secretory dysfunction in pancreatic beta cells. In addition, the finding that high dose FAs or glucose both induced an increase of ROS demonstrates the possible involvement of oxidative stress in FAs-induced beta cell dysfunction. This is consistent with the report (20) that high FAs or glucose-induced beta cell apoptosis was prevented by antioxidants, so that these cytotoxic effects could be mediated by oxidative stress. Mechanisms other than oxidative stress have been proposed to mediate fatty acid-induced beta cell dysfunction, including altered intracellular lipid partitioning, ceramide formation, activation of protein kinase C, inflammatory mechanisms, and endoplasmic reticulum (ER) stress; and glucotoxicity and lipotoxicity are believed to induce a synergistic loss of beta cells (1,21-25).

CD36 plays an important role in induction of fatty acid influx in pancreatic beta cells. One study demonstrated that induction of CD36 over-expression in INS-1 cells resulted in an increase in fatty acid uptake and attenuation of the normal potentiating effect of fatty acids on glucose stimulated insulin secretion (4). Findings of the present study demonstrated that even in normal fatty acid condition, high glucose induced expression of CD36 with increasing fatty acid influx and ROS was accompanied by a decrease in insulin secretion. Therefore, it is proposed that regardless of concentration of fatty acids, insulin secreting cells exposed to high glucose show increased fatty acid uptake resulting in beta cell dysfunction, at this time, CD36 plays an important role. It is suggested that elevated levels of glucose or fatty acids might regulate partitioning of calories into cells by induction of genes like CD36 that promote fatty acid uptake and triglyceride deposition, which contribute to acceleration of insulin resistance, cellular dysfunction, and atherosclerosis (26,27). Several studies have demonstrated that suppression of CD36 expression in insulin producing cells resulted in decreased fatty acid uptake and increased insulin secretion (28,29), and our previous study also demonstrated that suppression of CD36 by transfection with CD36 siRNA resulted in decreased oxidative stress and improved glucose stimulated insulin secretion in INS-1 cells (5). These findings suggested that inhibition of CD36 could be a target for prevention of glucotoxicity in pancreatic beta cells.

**DISCUSSION**

Findings of the present study demonstrated that ezetimibe reversed high glucose induced increased CD35 expression, palmitate influx, and ROS levels and also increased insulin secretion in INS-1 cells and primary rat islet cells. There is a controversy regarding whether or not the effect of elevated FAs on pancreatic beta cells is beneficial (16-19). However, it is widely accepted that prolonged exposure to elevated FAs along with high glucose causes pancreatic β-cell dysfunction and apoptosis, resulting in glucolipotoxicity (1). Findings of the present study demonstrated that high level of FAs led to an increase in oxidative stress and a decrease in insulin mRNA expression, but did not cause impairment of GSIS. The reasons why the effects of FAs on beta cell dysfunction in vitro have been various are the differences of sensitivity to the cytotoxic effects of FAs between clonal cells and primary beta cells, the disparity of concentration of FAs used in vitro, and lack of concern for the concentration of potent FAs fraction unbound to bovine serum albumin (BSA) (1).
Ezetimibe blocks absorption of Niemann-Pick C1-Like 1 (NPC1L1)-mediated cholesterol in the apical brush border membrane of jeunal enterocytes (6). Recently, ezetimibe has also been reported to decrease the surface expression of CD36 (7-9). Therefore, ezetimibe seems to be able to prevent beta cell dysfunction by inhibition of CD36. The present study demonstrated that ezetimibe induced a decrease in expression of CD36, fatty acid uptake, and ROS, which were elevated in high glucose condition, and reversed the suppressed insulin secretion in INS-1 cells and primary rat islet cells. These findings are consistent with those of other studies reporting that ezetimibe-treated db/db mouse showed improvement of the first phase of insulin secretion, reduced β cell loss, and protected function of β cells (13), and chronic administration of ezetimibe in OLETF rats was effective in glycemic control and lowering free fatty acids accompanied with preservation of pancreatic beta cell mass (14). According to one report, ezetimibe could inhibit the activity of hepatic NPC1L1, reducing oxidative stress and ER stress, and then improve insulin resistance in the liver, resulting in glycemic control (12). However, few studies have reported on the mechanism underlying the effect of ezetimibe on pancreatic islets, saving the study reported by Yang et al. (14), in which ezetimibe induced a decrease in the activity of serum dipeptidyl peptidase-4 (DPP-4) and an increase in serum active glucagon, like peptide-1 (GLP-1) in OLETF rats, suggesting involvement of GLP-1 in the ezetimibe-mediated effects on pancreatic beta cells. However, there was an inconsistent report that treatment with ezetimibe in obese men did not affect the serum glucose-dependent insulinotropic polypeptide (GIP) and active GLP-1 (30). Therefore, results of the present study demonstrated that ezetimibe may have a beneficial effect on glucotoxicity in insulin secreting β-cells through inhibition of fatty acid influx via CD36.

In summary, high glucose increased CD36, fatty acid influx, and oxidative stress, resulting in impairment of insulin secretion, and ezetimibe reversed the insulin secretory dysfunction through inhibition of fatty acid influx via CD36 in pancreatic beta cells. Therefore, elevation of CD36 resulting from hyperglycemia, even at normal fatty acid level, may induce beta cell dysfunction through increase of fatty acid influx; it is proposed that aggressive correction of hyperglycemia with dyslipidemia may be needed in order to prevent glucotoxicity, even in diabetic patients with normal blood lipid levels.

DISCLOSURE

The authors have no potential conflicts of interest to disclose.

AUTHOR CONTRIBUTION

Study design: Yoon JS, Moon JS, Won KC, Lee HW. Data collection and analysis: Yoon JS, Moon JS. Writing: Yoon JS. Revision and submission: Yoon JS, Moon JS, Kim YW, Won KC, Lee HW. Manuscript approval: all authors.

ORCID

Jisung Yoon http://orcid.org/0000-0003-3091-3700
Jun Sung Moon http://orcid.org/0000-0003-1569-3068
Yong Woon Kim http://orcid.org/0000-0003-2668-9690
Kyu Chang Won http://orcid.org/0000-0001-5945-3395
Hyyoungwoo Lee http://orcid.org/0000-0002-0773-1581

REFERENCES

1. Poitout V, Robertson RP. Glucolipotoxicity: fuel excess and beta-cell dysfunction. Endocr Rev 2008; 29: 351-66.
2. Kim JW, Yoon KH. Glucolipotoxicity in pancreatic β-cells. Diabetes Metab J 2011; 35: 444-50.
3. Jacqueminet S, Briand I, Rouault C, Reach G, Poitout V. Inhibition of insulin gene expression by long-term exposure of pancreatic beta cells to palmitate is dependent on the presence of a stimulatory glucose concentration. Metabolism 2000; 49: 532-6.
4. Wallin T, Ma Z, Ogata H, Jørgensen IH, Iezzi M, Wang H, Wollheim CB, Björkhed Å. Facilitation of fatty acid uptake by CD36 in insulin-producing cells reduces fatty-acid-induced insulin secretion and glucose regulation of fatty acid oxidation. Biochim Biophys Acta 2010; 1801: 191-7.
5. Kim YW, Moon JS, Seo YJ, Park SY, Kim JY, Yoon JS, Lee IK, Lee HW, Won KC. Inhibition of fatty acid translocase cluster determinant 36 (CD36), stimulated by hyperglycemia, prevents glucotoxicity in INS-1 cells. Biochem Biophys Res Commun 2012; 420: 462-6.
6. Altmann SW, Davis HR Jr, Zhu LJ, Yao X, Hoos LM, Tetzloff G, Iyer SP, Maguire M, Golovko A, Zeng M, et al. Niemann-Pick C1 Like 1 protein is critical for intestinal cholesterol absorption. Science 2004; 303: 1201-4.
7. Kramer W, Gribg F, Corsiero D, Plenninger A, Frick W, Jühne G, Rhein M, Wendler W, Lottscheid F, Hochleitner EO, et al. Aminopeptidase N (CD13) is a molecular target of the cholesterol absorption inhibitor ezetimibe in the enterocyte brush border membrane. J Biol Chem 2005; 280: 1306-20.
8. Mina-Osorio P, Ortega E. Aminopeptidase-N (CD13) functionally interacts with FcgammaRs in human monocytes. J Leukoc Biol 2005; 77: 1008-17.
9. Orso E, Werner T, Wolf Z, Bandalik S, Kramer W, Schmitz G. Ezetimibe influences the expression of raff-associated antigens in human monocytes. Cytometry A 2006; 69: 206-8.
10. Hiramitsu S, Miyagishima K, Ishii J, Matsui S, Naruse H, Shino K, Kitagawa F, Ozaki Y. Effect of ezetimibe on lipid and glucose metabolism after a fat and glucose load. J Cardio 2012; 60: 395-400.
11. Tsunoda T, Nozue T, Yamada M, Mizuguchi I, Sasaki M, Michishita I. Effects of ezetimibe on atherogenic lipoproteins and glucose metabolism in patients with diabetes and glucose intolerance. Diabetes Res Clin Pract 2013; 100: 46-52.
12. Nomura M, Ishii H, Kawakami A, Yoshida M. Inhibition of hepatic Niemann-Pick C1-like 1 improves hepatic insulin resistance. Am J Physiol Endocrinol Metab 2009; 297: E1030-8.
13. Zhong Y, Wang J, Gu P, Shao J, Lu B, Jiang S. Effect of ezetimibe on insulin
secretion in db/db diabetic mice. Exp Diabetes Res 2012; 2012: 420854.

14. Yang SJ, Choi JM, Kim L, Kim BJ, Solhn JH, Kim WJ, Park SE, Rhee EJ, Lee WY, Oh KW, et al. Chronic administration of ezetimibe increases active glucagon-like peptide-1 and improves glycemic control and pancreatic beta cell mass in a rat model of type 2 diabetes. Biochem Biophys Res Commun 2011; 407: 153-7.

15. Won KC, Moon JS, Eun MJ, Yoon JS, Chun KA, Cho IH, Kim YW, Lee HW. A protective role for heme oxygenase-1 in INS-1 cells and rat islets that are exposed to high glucose conditions. J Korean Med Sci 2006; 21: 418-24.

16. Robertson RP, Harmon J, Tran PO, Poitout V. Beta-cell glucose toxicity, lipotoxicity, and chronic oxidative stress in type 2 diabetes. Diabetes 2004; 53 Suppl 1: S119-24.

17. Boden G, Chen X, Rosner J, Barton M. Effects of a 48-h fat infusion on insulin secretion and glucose utilization. Diabetes 1995; 44: 1239-42.

18. Paolisso G, Tatarnni PA, Foley JE, Bogardus C, Howard BV, Ravussin E. A high concentration of fasting plasma non-esterified fatty acids is a risk factor for the development of NIDDM. Diabetologia 1995; 38: 1213-7.

19. Leung N, Sakaue T, Carpentier A, Uffelman K, Giacca A, Lewis GF. Prolonged increase of plasma non-esterified fatty acids fully abolishes the stimulatory effect of 24 hours of moderate hyperglycaemia on insulin sensitivity and pancreatic beta-cell function in obese men. Diabetologia 2004; 47: 204-13.

20. Piro S, Anello M, Di Pietro C, Lizzio MN, Patané G, Rabuazzo AM, Vigneri R, Purrello C, Purrello M. Chronic exposure to free fatty acids or high glucose induces apoptosis in rat pancreatic islets: possible role of oxidative stress. Metabolism 2002; 51: 1340-7.

21. Giacca A, Xiao C, Oprescu AI, Carpentier AC, Lewis GF. Lipid-induced pancreatic β-cell dysfunction: focus on in vivo studies. Am J Physiol Endocrinol Metab 2011; 300: E255-62.

22. Lupi R, Dotta F, Marselli L, Del Guerra S, Masini M, Santangelo C, Patané G, Boggi U, Piro S, Anello M, et al. Prolonged exposure to free fatty acids has cytostatic and pro-apoptotic effects on human pancreatic islets: evidence that β-cell death is caspase mediated, partially dependent on ceramide pathway, and Bcl-2 regulated. Diabetes 2002; 51: 1437-42.

23. Eitel K, Staiger H, Rieger J, Mischak H, Brandhorst H, Brendel MD, Bretzel RG, Häring HU, Kollerer M. Protein kinase C delta activation and translocation to the nucleus are required for fatty acid-induced apoptosis of insulin-secreting cells. Diabetes 2003; 52: 991-7.

24. Busch AK, Cordery D, Denyer GS, Biden TJ. Expression profiling of palmitate- and oleate-regulated genes provides novel insights into the effects of chronic lipid exposure on pancreatic beta-cell function. Diabetes 2002; 51: 977-87.

25. Kharroubi I, Ladrière L, Cardozo AK, Dugas Z, Cnop M, Eizirik DL. Free fatty acids and cytokines induce pancreatic β-cell apoptosis by different mechanisms: role of nuclear factor-kappaB and endoplasmic reticulum stress. Endocrinology 2004; 145: 5087-96.

26. Hajri T, Abumrad NA. Fatty acid transport across membranes: relevance to nutrition and metabolic pathology. Annu Rev Nutr 2002; 22: 383-415.

27. Griffin E, Re A, Hamel N, Fu C, Bush H, McCaffrey T, Asch AS. A link between diabetes and atherosclerosis: glucose regulates expression of CD36 at the level of translation. Nat Med 2001; 7: 840-6.

28. Dalgaard LT, Thams P, Gaarn LW, Jensen J, Lee YC, Nielsen JH. Suppression of FAT/CD36 mRNA by human growth hormone in pancreatic β-cells. Biochem Biophys Res Commun 2011; 410: 345-50.

29. Noushmehr H, D’Amico E, Farilla L, Hui H, Wawrowsky KA, Mlynski W, Doria A, Abumrad NA, Perfetti R. Fatty acid translocase (FAT/CD36) is localized on insulin-containing granules in human pancreatic beta-cells and mediates fatty acid effects on insulin secretion. Diabetes 2005; 54: 472-81.

30. Kikuchi K, Nezu U, Inazumi K, Miyazaki T, Ono K, Orike K, Shirakawa J, Sato K, Koike H, Wakasugi T, et al. Double-blind randomized clinical trial of the effects of ezetimibe on postprandial hyperlipidaemia and hyperglycaemia. J Atheroscler Thromb 2012; 19: 1093-101.